CTx-1301
Jump to navigation
Jump to search
 | It has been suggested that this article be merged into dexmethylphenidate. (Discuss) Proposed since November 2023. |
CTx-1301 is an experimental medication that is an extended-release formulation of dexmethylphenidate that has a half life more than an hour longer than extended-release dexmethylphenidate (d-MPH-ER). It is under development for ADHD.[1][2][3][4][5]
References
- ^ Brady, Linda S.; Lisanby, Sarah H.; Gordon, Joshua A. (3 August 2023). "New directions in psychiatric drug development: promising therapeutics in the pipeline". Expert Opinion on Drug Discovery. 18 (8): 835–850. doi:10.1080/17460441.2023.2224555. PMID 37352473. S2CID 259240509.
- ^ Childress, Ann C.; Beltran, Nathalie; Supnet, Carl; Weiss, Margaret D. (2 January 2021). "Reviewing the role of emerging therapies in the ADHD armamentarium". Expert Opinion on Emerging Drugs. 26 (1): 1–16. doi:10.1080/14728214.2020.1846718. PMID 33143485. S2CID 226251694.
- ^ Ryst, Erika; Childress, Ann (2023). "An updated safety review of the current drugs for managing ADHD in children". Expert Opinion on Drug Safety: 1–16. doi:10.1080/14740338.2023.2271392. PMID 37843488. S2CID 264144450.
- ^ Harris, Elaine (1 February 2018). "Industry update: what is new in the field of therapeutic delivery?". Therapeutic Delivery. 9 (3): 155–161. doi:10.4155/tde-2017-0117.
- ^ Childress, Ann C.; Komolova, Marina; Sallee, F. Randy (2 November 2019). "An update on the pharmacokinetic considerations in the treatment of ADHD with long-acting methylphenidate and amphetamine formulations". Expert Opinion on Drug Metabolism & Toxicology. 15 (11): 937–974. doi:10.1080/17425255.2019.1675636. PMID 31581854. S2CID 203660100.